Home › Funds › Ilex Capital Partners (UK) LLP › ABT

Ilex Capital Partners (UK) LLP position in ABT

ABBOTT LABORATORIES · Health Care

Ilex Capital Partners (UK) LLP reported holding 480,855 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$47.5M, representing 0.92% of its reported portfolio and ranking #30 among its reported holdings. Ilex Capital Partners (UK) LLP has disclosed ABT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)480.86K sh
Reported value held$47.52M
Portfolio Weight0.92%
First reportedQ2 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Ilex Capital Partners (UK) LLP's ABT position evolved

Ilex Capital Partners (UK) LLP first disclosed a stake in ABT in Q2 2026 at 1,081,748 shares (US$98.2M). Across 2 filings, Ilex Capital Partners (UK) LLP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 480,855 shares valued at US$47.5M — a reduction of -600,893 shares quarter over quarter.. Notable position changes include a 56% trim in Q3 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 1.08M $98.16M New
Q3 2026 480.86K $47.52M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Ilex Capital Partners (UK) LLP held ABT?

Ilex Capital Partners (UK) LLP has disclosed ABT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Ilex Capital Partners (UK) LLP's current position in ABT?

As of Q3 2026, Ilex Capital Partners (UK) LLP holds 480.86K shares of ABT (ABBOTT LABORATORIES), valued at $47.52M, representing 0.92% of its reported portfolio and ranking #30.

Has Ilex Capital Partners (UK) LLP been buying or selling ABT?

In the latest 13F filing (Q3 2026), Ilex Capital Partners (UK) LLP reduced its position in ABT.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.